

A Hidden Opponent: Should Athletes Need Pneumococcal Protection

Authors

Deepak Nagra^{1,3}, Bako Nouri², Tim Blake¹, Maryam Adas³, Mark Russell³, James Galloway³
ORCID: Deepak Nagra: 0000-0002-1307-6528

Received: 06 March 2026
Accepted: 04 April 2026
Published: 24 April 2026

¹ Department of Rheumatology, University Hospitals Coventry & Warwickshire

² University Hospitals Manchester NHS Trust

³ Centre for Rheumatic Disease, King's College London

DOI: [10.67452/EMSR.2026.002](https://doi.org/10.67452/EMSR.2026.002)

Corresponding author: Deepak Nagra

Abstract

Background: Elite athletes represent an under-recognised risk group for invasive pneumococcal disease (IPD). Despite documented vulnerabilities — including immune dysregulation from intense training, upper airway dysbiosis, close-contact living environments, and extensive international travel — pneumococcal vaccination is not currently included in UK travel immunisation guidance for athletes.

Methods: We review the existing evidence on respiratory infections in elite athletes, highlight relevant outbreak data, and examine the immunological basis for increased susceptibility to pneumococcal disease in this population.

Results: Respiratory infections affect approximately 4.7 athletes per 1000 athlete days, with substantially higher rates in non-elite populations. Major international sporting events have recorded hundreds of respiratory tract infections, yet causative bacterial organisms remain poorly characterised. Parallels with military cohorts — another high-risk group with comparable living conditions — further support the case for targeted vaccination.

Conclusions: Pneumococcal vaccination should be incorporated into pre-travel health assessments for elite athletes, particularly those undertaking extended international stays or competing in close-contact environments. The approval of PCV20 offers an important opportunity to expand protection. Further research into bacterial respiratory infections in this population is urgently needed to inform evidence-based vaccination policy.

Keywords: pneumococcal vaccination, elite athletes, invasive pneumococcal disease, respiratory infections, sports medicine, PCV20, immunisation, travel health

COMMENTARY

Invasive pneumococcal disease is a preventable threat. Yet elite athletes remain off the radar for vaccination despite being a risk group¹⁻³. This can be due to underlying co-morbidities or the nature of increased and intense travel schedules within the sports community. Athletes are also susceptible to infections due to reduced circulating memory T cells and upper airway dysbiosis⁴. Pneumococcal vaccination is not currently included in the UK's Green Book guidance for travel-related

immunisation, nor is the travelling athlete listed as a risk group in chapter 25 amongst those who should be recommended for pneumococcal vaccination.

Athletes are frequently exposed to close-contact environments such as shared accommodation, team transport, and commercial flights^{5,6}. These conditions, combined with the physical stress of intense training, disrupted circadian rhythms, and potential exposure to unfamiliar pathogens, may increase vulnerability to respiratory infections, including *Streptococcus pneumoniae*⁷. While invasive pneumococcal disease is uncommon in young healthy adults, recent outbreaks of IPD across multiple continents remain a concern. Studies have demonstrated outbreaks of respiratory illness in military cohorts, often linked to close-contact living and strenuous activity⁸. Although sports teams are not routinely considered high-risk by public health guidance, the parallels are notable.

On the international stage, the 2002 Winter Olympics saw a short-lived influenza outbreak. Previous literature has highlighted the risk of meningococcal disease at the FIFA World Cup, with the need for robust vaccination regimes⁹. Despite recognition of other pathogens, pneumococcal disease remains under-researched, creating an important evidence gap, warranting further investigation in the current climate of evidence-based policy. A second outbreak in 2003 of pneumococcal infections was reported in a cohort of college students, for which one of the risks was being part of the sports team. This infection was thought to be atypical with the absence of a polysaccharide capsule and at the time could not be serotyped¹⁰. In a study examining T cell profiles in Olympics athletes, T regulatory cell dysfunction with concomitant dysbiosis of the upper respiratory tract was a key driver in respiratory infections in this athlete population⁴. Disruption in T cell populations was thought to be driven partly by strenuous exercise when compared to healthy controls.

A systematic review of respiratory infections in athletes reported a rate of 4.7 athletes per 1000 athlete days becoming infected¹¹. The majority of reporting has been on viral infections with few studies on bacterial disease¹². Rates were higher for non-elite athletes with rates of 8.7 per 1000 athlete days. In a study reporting on illness in the Rio 2016 paralympic games respiratory infections were reported in 8 of the 511 participants¹³. Amongst the Olympic games in 2016, there were 346 respiratory tract infections¹⁴. When compared to the London 2012 paralympic, out of 157 infections, 50% represented respiratory tract infections, although the causative organism was not reported on¹⁵. 61% of beach volleyball players reported respiratory infections at the London 2012 Olympics¹⁶.

The 20 valent conjugate vaccine (PCV20) received approval from the Medicines and Health Regulatory Authority (MHRA) in May 2025 and is set to replace the polysaccharide vaccine (PPSV23) within the United Kingdom to mirror US vaccination procedures¹⁷. PCV20 can offer protection against 8 unique pneumococcal serotypes not covered in PPSV23, with the addition of serotypes 15,16 and 35 which are becoming increasingly resistant to antimicrobial therapy, and serotype 23 for which outbreaks have occurred in densely populated areas.

Invasive pneumococcal disease is a common and preventable infection amongst the sporting community, with vaccination requirements highlighted as a need over 30 years ago, public health interventions for this risk group are yet to be addressed within the UK¹⁸. We suggest that pneumococcal vaccination be considered in the pre-travel health assessments of athletes, particularly when extended stays, shared accommodation, or travel to low-resource settings are involved. Although briefly mentioned within the 2022 International Olympic Committee (IOC) consensus statement on acute respiratory illness in the athlete¹⁹, vaccination in this group. With a great deal of national and international guidance for the covid-19 vaccine following the pandemic, the pneumococcal vaccination efforts are yet to receive similar recognition.



Existing literature on vaccination efforts amongst this cohort remains limited,⁶ with few studies reporting on pneumococcal disease alone and rather respiratory infections as a whole. Through this work we aim to highlight the need to study further respiratory tract infections in elite athletes with attention to bacterial infections in order to adjust guidance on health screening and vaccination, particularly for those competing internationally or living in close-contact environments.

DECLARATION

The authors have declared no conflicts of interest.

REFERENCES

1. Lin L, Decker CF. Respiratory tract infections in athletes. *Dis Mon.* 2010;56(7):407-13.
2. Raji Y, Knapik DM, Schroeder AN, Voos JE. Common sports infectious disease. *HSS J.* 2023;19(3):351-7.
3. Ruuskanen O, Valtonen M, Heinonen OJ, Waris M, Mertsola J. Vaccinations for elite athletes. *Vaccines (Basel).* 2025;13(9).
4. Cuthbertson L, Turner SEG, Jackson A, et al. Evidence of immunometabolic dysregulation and airway dysbiosis in athletes susceptible to respiratory illness. *EBioMedicine.* 2022;79:104024.
5. Ruuskanen O, Dollner H, Luoto R, Valtonen M, Heinonen OJ, Waris M. Contraction of respiratory viral infection during air travel: an under-recognized health risk for athletes. *Sports Med Open.* 2024;10(1):60.
6. Tafuri S, Sinesi D, Gallone MS. Vaccinations among athletes: evidence and recommendations. *Expert Rev Vaccines.* 2017;16(9):867-9.
7. Smoot MK, Hosey RG. Pulmonary infections in the athlete. *Curr Sports Med Rep.* 2009;8(2):71-5.
8. Banerjee A, Kalghatgi AT, Saiprasad GS, et al. Outbreak of pneumococcal pneumonia among military recruits. *Med J Armed Forces India.* 2005;61(1):16-21.
9. Zuckerman JN, Broker M, Worth C. 2010 FIFA World Cup South Africa: travel health issues and new options for protection against meningococcal disease. *Travel Med Infect Dis.* 2010;8(2):68-73.
10. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical *Streptococcus pneumoniae*. *N Engl J Med.* 2003;348(12):1112-21.
11. Derman W, Badenhorst M, Eken MM, et al. Incidence of acute respiratory illnesses in athletes: a systematic review and meta-analysis by a subgroup of the IOC consensus on acute respiratory illness in the athlete. *Br J Sports Med.* 2022;56(11):630-8.
12. Ruuskanen O, Luoto R, Valtonen M, Heinonen OJ, Waris M. Respiratory viral infections in athletes: many unanswered questions. *Sports Med.* 2022;52(9):2013-21.
13. Derman W, Schwellnus MP, Jordaan E, et al. Sport, sex and age increase risk of illness at the Rio 2016 Summer Paralympic Games: a prospective cohort study of 51 198 athlete days. *Br J Sports Med.* 2018;52(1):17-23.
14. Soligard T, Steffen K, Palmer D, et al. Sports injury and illness incidence in the Rio de Janeiro 2016 Olympic Summer Games: a prospective study of 11 274 athletes from 207 countries. *Br J Sports Med.* 2017;51(17):1265-71.
15. Derman W, Schwellnus M, Jordaan E. Clinical characteristics of 385 illnesses of athletes with impairment reported on the WEB-IISS system during the London 2012 Paralympic Games. *PM R.* 2014;6(8 Suppl):S23-30.
16. Engebretsen L, Soligard T, Steffen K, et al. Sports injuries and illnesses during the London Summer Olympic Games 2012. *Br J Sports Med.* 2013;47(7):407-14.



-
17. Nikhab A, Patel T, Rooney G, et al. Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England. *Vaccine*. 2026;75:128246.
 18. Barnett ED, Klein JO, Teele DW. Pneumococcal vaccine for Olympic athletes and visitors to Spain. *N Engl J Med*. 1992;326(23):1572.
 19. Schwellnus M, Adami PE, Bougault V, et al. International Olympic Committee (IOC) consensus statement on acute respiratory illness in athletes' part 1: acute respiratory infections. *Br J Sports Med*. 2022.